U.S. markets open in 8 hours 30 minutes

Lucira Health, Inc. (LHDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W
5.06+0.02 (+0.40%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
Previous Close5.04
Open5.19
Bid0.00 x 2200
Ask0.00 x 900
Day's Range4.97 - 5.19
52 Week Range4.23 - 37.99
Volume224,549
Avg. Volume2,250,425
Market Cap195.181M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    LUCIRA™ HEALTH Hires Chief Revenue Officer Kevin Collins

    Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced medtech veteran Kevin Collins has joined the company as Chief Revenue Officer with global revenue responsibility.

  • Is Lucira Health a Good Stock to Buy Right Now?
    Motley Fool

    Is Lucira Health a Good Stock to Buy Right Now?

    Shares of Lucira Health (NASDAQ: LHDX) exploded out of the gate when the company made its stock market debut in February. Lucira Health's over-the-counter COVID-19 tests racked up millions of dollars in sales during the first three months of 2021, leading some investors to wonder if this beaten-down stock can bounce back.

  • Lucira Health to Participate in William Blair 41st Annual Growth Stock Conference
    GlobeNewswire

    Lucira Health to Participate in William Blair 41st Annual Growth Stock Conference

    EMERYVILLE, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will be participating in the William Blair 41st Annual Growth Stock Conference. Lucira Health’s management is scheduled to participate in the conference on Wednesday, June 2, 2021, at 10:40 a.m. PT / 1:40 p.m. ET. Interested parties can access the live and archived webcast at ir.lucirahealth.com. About Lucira HealthLucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira’s testing platform produces lab quality molecular testing in a single-use, consumer-friendly, palm size test kit powered by two AA batteries. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular tests results anywhere and anytime. The LUCIRA CHECK IT (OTC) and LUCIRA COVID-19 All-In-One (RX) Test Kits are designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. For more information, visit www.lucirahealth.com. Investor Contact Greg Chodaczek Investorrelations@lucirahealth.com347-620-7010 Media Contact Kevin Knight media@lucirahealth.com 206-451-4823